ACCESS TO ADVANCED HEALTH INSTITUTE

ACCESS TO ADVANCED HEALTH INSTITUTE specializes in translational research and development of novel biotechnological and life science solutions for public health security. Their core capabilities center on the design, preclinical advancement, and clinical evaluation of vaccine candidates targeting biodefense threats, antimicrobial-resistant infections, and emerging infectious diseases. The contractor demonstrates deep expertise in synthetic vaccine platforms, intranasal delivery systems, and adjuvant formulation, with a focus on pathogen-specific immunogens for pathogens such as Entamoeba histolytica. Technical proficiency includes molecular cloning, immunogenicity assessment, and preclinical validation frameworks aligned with NIH and HHS regulatory pathways. Their distinguishing strength lies in bridging early-stage biotech innovation with translational readiness, particularly in under-resourced threat categories where traditional vaccine development pipelines are insufficient. The contractor maintains a consistent and focused relationship with the Department of Health and Human Services, primarily through the National Institutes of Health and the National Institute of Allergy and Infectious Diseases. Work performed under HHS funding centers on high-priority public health threats, including biodefense preparedness and antimicrobial resistance mitigation, indicating a trusted partnership in advancing mission-critical biomedical research. Their industry focus is narrowly aligned with NAICS 541714 and 541715, reflecting exclusive engagement in non-nano biotechnology R&D and broader life sciences research. This positions them as a specialized provider in the federal biodefense and infectious disease innovation ecosystem, serving as a critical link between academic discovery and government-funded product development. As an 8H-certified entity based in Seattle, WA, ACCESS TO ADVANCED HEALTH INSTITUTE operates as a small business with targeted expertise in government-contracted biomedical R&D. While no additional federal certifications are disclosed, their sustained engagement with HHS underscores a credible track record in meeting stringent federal research standards and deliverables.